Cullinan Oncology is a biopharmaceutical company developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The company assembles a portfolio of single-asset oncology opportunities through both internal and external means. It operates a unique, cost-efficient model that leverages a central management team and shared services to drive speed and efficiency. Cullinan announced the closing of an oversubscribed $131.2 million Series C financing. SVB Leerink served as the exclusive placement agent for the private placement. The financing reinforces the company's capital base as it pursues advancement of its portfolio of oncology assets. Cullinan Oncology builds a diversified portfolio of internally developed and externally sourced oncology assets, advancing both small molecules and biologics. The company focuses on efficiently developing single-asset opportunities through strategic partners and a shared-services platform. Its pipeline includes Cullinan Pearl, an oral tyrosine kinase inhibitor targeting EGFR exon 20 mutations, and a mix of targeted small molecules, first-in-class immunotherapies, bispecific antibodies and multifunctional fusion proteins. Since its founding in October 2017, Cullinan has progressed seven assets through in vivo proof-of-concept studies or into human clinical testing. The company completed a $98.5 million Series B to support ongoing clinical trials across its portfolio. Recent leadership moves include hiring Jon Wigginton, M.D., as Chief Medical Officer and promoting Jennifer Michaelson, Ph.D., to Chief Development Officer, Biologics. Cullinan is based in Cambridge, Mass., and emphasizes distributing risk and maximizing optionality through its portfolio approach. Cullinan Oncology was created by MPM Capital to develop high-value oncology therapeutics using a capital-efficient, portfolio-based model. The company builds and manages a diversified pipeline of internally developed and externally sourced oncology assets under a single experienced team. Its scalable approach minimizes fixed costs and inefficiencies via strategic partnerships and a shared services platform. Cullinan intends to capitalize on scientific breakthroughs across a broad range of cancer targets and therapeutic modalities to drive better patient outcomes. The company emphasizes distributing risk while maximizing optionality across multiple programs. The organization is led by a senior team of oncology researchers and biopharma executives, including co-founder and CSO Patrick Baeuerle and CEO Owen Hughes.

Total raised

$380M

Funding rounds

3

Latest round

Series C

Latest activity

Dec 2020